Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16781803 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL16631246 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL17082394 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL18871288 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL16781808 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL16631577 | 0.88 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL16631431 | 0.85 | SLC28A1 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL16631263 | 0.83 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL16781790 | 0.83 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 | |
| SCHEMBL18852567 | 0.83 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-2918275-B1 | Alternative nucleic acid molecules and uses thereof | MODERNA THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.